Skip to main content

Share story

Science

Gene therapy trial characterised by hype and hubris ends in a child's death

Gene therapy trial characterised by hype and hubris ends in a child's death Image: Primary
A six-year-old girl has died in a gene editing gene therapy trial in China that went wrong, the journal Science reports. Seven days after the girl's medical team infused trillions of viruses carrying the recipe for the gene editing tool, in this case a base editor, into her spinal fluid, she died of a severe immune reaction linked to the therapy. The hospital's ethics board concluded her death was "definitely related" to the treatment two days after she died. The trial was funded in part by $860,000 the parents had scraped together from their own savings and from relatives. The hospital had allowed scientist Zilong Qiu's experimental treatment to proceed under a regulatory provision that does not require approval from national regulators. Her condition was not life-threatening. It was a clinical trial of one.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from GMWatch and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Infrastructure Science
Infrastructure Science

Quilty Space projects shortfall of about 150 launches through 2030

The world outside China faces a shortfall of about 150 rocket launches through 2030 against demand from satellite operators and civil space agencies, analytics firm Quilty Space estimates in a new report.

AI Science
AI Science

Insilico says AI-discovered Rentosertib has entered Phase III trials

Insilico Medicine says Rentosertib, its generative AI-discovered drug candidate also known as ISM001-055, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. The company described the clinical advance in an announcement carried by News-Medical.Net.

Science Products
Science Products

PopVax offers personalized cancer vaccine manufacturing at expected $300,000 cost

PopVax's RNA Foundry is offering contract development and manufacturing of personalized cancer vaccine candidates at its Hyderabad facility. The company expects most projects to cost around $300,000 and take 8-10 weeks, depending on manufacturing slot availability.